Table 2.
Risk analysis results of DMRs methylation levels of imprinted genes and CHD occurrence
| Imprinted genes | Quantile percentages | Controls n (%) |
CHD n (%) |
Adjusted ORa (95% CIb) |
Adjusted P value |
|---|---|---|---|---|---|
| GRB10 | Q1c (< 39.67%) | 6(26.1%) | 1(4%) | 1(reference) | |
| Q2–Q3 d (39.67%–44%) | 11(47.8%) | 3(12%) | 1.64(0.14–19.39) | 0.696 | |
| Q4e (> 44%) | 6(26.1%) | 21(84%) | 21.00(2.10–210.14) | 0.01 | |
| MEST | Q1 (< 49.36%) | 5(22.7%) | 1(5%) | 1(reference) | |
| Q2–Q3 (49.36%–56.07%) | 12(54.5%) | 9(45%) | 3.75(0.371–37.95) | 0.263 | |
| Q4 (> 56.07%) | 5(22.7%) | 10(50%) | 10.00(0.907–110.28) | 0.06 | |
| PEG10 | Q1 (< 45.2%) | 5(22.7%) | 14(56%) | 16.80(1.60–176.23) | 0.019 |
| Q2–Q3 (45.2%–55.7%) | 11(50%) | 10(40%) | 5.46(0.56–53.52) | 0.145 | |
| Q4 (> 55.7%) | 6(27.3%) | 1(4%) | 1(reference) | ||
| NAP1L5 | Q1 (< 67.14%) | 6(26.1%) | 9(45%) | 3.50(0.64–19.20) | 0.149 |
| Q2–Q3 (67.14%–71.29%) | 10(43.5%) | 8(40%) | 1.87(0.36–9.64) | 0.456 | |
| Q4 (> 71.29%) | 7(30.4%) | 3(15%) | 1(reference) | ||
| INPP5Ff | Q1 (< 70.39%) | 4(23.5%) | 17(77.3%) | 11.06(2.47–49.53) | 0.002 |
| Q2–Q4 (≥ 70.39%) | 13(76.5%) | 5(22.7%) | 1(reference) | ||
| PLAGL1 | Q1 (< 40.76%) | 6(24%) | 11(42.3%) | 11.00(1.06–114.09) | 0.045 |
| Q2–Q3 (40.76%–45.82%) | 13(52%) | 14(53.8%) | 6.46(0.68–61.16) | 0.104 | |
| Q4 (> 45.82%) | 6(24%) | 1(3.8%) | 1(reference) | ||
| MEG3f | Q1 (< 41.83%) | 6(25%) | 16(80%) | 12.00(2.86–50.31) | 0.001 |
| Q2–Q4 (≥ 41.83%) | 18(75%) | 4(20%) | 1(reference) |
aOdds ratio
bConfidence interval
c25th percentile
d25th percentile to 75th percentile
e75th percentile. Cut-off value was defined as 25th and 75th percentiles of the control group methylation level. Adjusted for sex by logistic regression
fIndicates that the maximum value of the imprinting gene cases was less than 75% of control group and could not be calculated, so there were divided into two groups